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Broad Institute: Bringing Genomics
to Real-World Medicine
In June 2003, the scientific and g
medical communities at MIT, Har- i
vard University and its affiliated f
hospitals, and the Whitehead Insti- j
tute banded together as collabo- t
rating partners to form the Eli and m
Edythe L. Broad Institute based in s
Cambridge, MA. The Broad Institute, m
established with initial funding from c
a $100 million philanthropic donation
from the Los Angeles-based Broad
Cfamily, was primarily viewed as a
Dmarriage between the Whitehead In-
“stitute’s Center for Genome Re-
tsearch (WICGR) and the Harvard In-
istitute of Chemistry and Cell Biology
v(ICCB). Eli Broad, founder and chair-
aman of AIG SunAmerica, Inc., ex-
splains, “The purpose of the Broad
aInstitute is to create a new type of
research institute to build on the ac-
complishments of the human ge-
nome project and to move to clin- “
ical applications to both prevent
tand cure diseases.”
The nascent institute includes four m
core faculty members leading four ifoundational programs in genomics,
mchemical biology, medical and pop-
ulation genetics, and cancer medi- p
cine. When fully staffed over the next tfive years, the institute will have 12
bcore faculty members on board at
the new 230,000-square-foot Cam- S
bridge facility, scheduled to be com- fpleted in 2006. Among the four core
members are former ICCB Director
Stuart Schreiber and former WICGR
sDirector Eric Lander, who now directs
ithe Broad Institute. “In the early days,
swhen Eric and I were discussing for-
Omally merging these two institutions,
emy thinking was that the Broad rep-
fresented the promise of integrating
ugenomics and chemical biology,” re-
dcalls Schreiber. But today, that idea
stoo narrowly describes the Institute’s
fmission. “It is the integration of ge-
Lnomics and chemical biology in part-
wnership with the medical side of can-
wcer, psychiatric disease, infectious
rdisease, and metabolic disease,”
ysays Schreiber. Within the scope of
othe Broad’s current research effort
are the four founding scientific pro- wrams, three initiatives in metabolic, c
nfectious, and psychiatric disease, t
ive scientific platforms, and 11 ma- a
or projects. Researchers also par- h
icipate in numerous other projects, c
any involving partners from out-
ide of the MIT and Harvard com- i
unities and a few with for-profit l
ompanies. t
k
complex Human Genetic piseases v
Today, we are constantly reminded “
hat the human genome sequence i
s just a reference that by itself is of t
ery little value,” says Schreiber. To p
dd that value, the Broad has cho- m
en to focus on medical arenas with n
significant underlying genetic ba- t
a
t
e[The Broad Institute] is
fhe integration of geno- w
ics and chemical biology
In partnership with the
hedical side of cancer, g
sychiatric disease, infec- t
aious disease, and meta-
Solic disease.” —Stuart d
chreiber, Broad Institute s
oaculty member
M
p
eis rather than Mendelian diseases
tn which a single gene change is
ttrong enough to cause disease.
nne example is the Psychiatric Dis-
sase Initiative (PDI), dedicated to
inding the multiple genes contrib-
ting to schizophrenia and bipolar N
isease risk. In 2004, the Broad In- T
titute recruited Edward Scolnick, B
ormer president of Merck Research c
aboratories, as director of the PDI, H
here he works with Pamela Sklar, W
ho has been researching psychiat- m
ic disease genetics for the past six s
ears. “Ed Scolnick provides a vision Y
f disease that takes into account t
hat the real challenges are and the sombination of approaches needed
o solve the big problems in psychi-
tric disease,” says Schreiber. “And
e was able to nucleate a group of
olleagues in the area.”
“The Broad is unique because it
s a collaborative institute and it al-
ows expensive and complicated
echnology and the people who
now how to use it to be applied in
ollaborative ways to major medical
roblems that otherwise would be
ery difficult to do,” says Scolnick.
The people, technology, and fund-
ng are here now at this unique time
o apply the best of this so-called
ostgenomics era to significant
edical projects.” Adds Sklar, “I am
ow in a position where I can be at
he forefront of developing genetic
nalyses and techniques and apply
hem very rapidly to psychiatric dis-
ase. That had been missing in the
ield of psychiatric research as a
hole.”
“Eric Lander has set up the Broad
nstitute in a very efficient way to
ave core technologies and core
roups operate in large collabora-
ive projects in much the same way
company laboratory does,” says
colnick, though he adds that it
oes not yet have financial re-
ources available to it on the scale
f a pharmaceutical company like
erck. This means the research
ace is slower than in a company
nvironment. “But no company has
he technology that is available here
o be able to do the things with ge-
etics that the Broad can do,” he
ays.
etwork of Collaborations
wo years after its founding, the
road includes 60 associated fa-
ulty members, drawn from MIT,
arvard and its hospitals, and the
hitehead Institute. “That is what is
ost impressive about the Broad,”
ays Michael Snyder, Director of the
ale Center for Genomics and Pro-
eomics, whose center is also pur-
uing advances in genomics re-
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718search. “They have clearly attracted m
some of the leading figures in their m
fields.” Each member of the Broad m
community, including the four core “
faculty members, retains member- w
ship in his or her home department g
and institution. Associate members p
participate with the Broad on two- f
tyear membership cycles.
“A lot of the interaction at the u
Broad is intended to enable larger t
collaborations that typically cannot i
be undertaken or are difficult to un-
dertake at individual labs or to be a
funded in individual labs,” says Pat- “
rick Kleyn, director of scientific u
planning at the institute. An exam- h
ple of that is the inhibitor RNA t
(RNAi) Consortium project. “That is e
a collaboration initially founded by o
a few investigators around Cam- h
bridge and Boston who came to- t
gether realizing it would be more l
effective and efficient to pool re- e
sources,” explains Kleyn. “It soon l
became clear it would make sense c
to make a library of inhibitory RNA r
clones, but it would require serious w
money and management.” Building t
on the strengths of people with sci- d
entific expertise by providing the p
large-scale management experience, g
the Broad helped organize and cur- f
rently is the base of operations for R
the RNAi Consortium. Announced in m
March 2005, the RNAi Consortium S
includes 11 biomedical organiza- A
tions focused on creating a library s
of gene inhibitors based on RNA in- y
terference. The short RNA hairpin i
sequences created will be used to b
discover the key genes involved in s
normal physiology and disease by i
targeting 15,000 human genes and “
15,000 mouse genes, the hope be- t
ing that this will yield new targets n
for drug discovery. A total of 150,000 d
custom-designed short hairpin RNAs
will be created and validated. All w
wreagents and discoveries will be
disseminated to the worldwide sci- a
entific community. w
“The Broad is taking on big cut- s
cting-edge projects,” says Snyder.
One example cited is the Interna- g
ational Haplotype Map Project, an in-
ternational research effort mapping t
ccommon patterns of human genetic
variation known as haplotypes, led e
uin part by the Broad’s David Alt-
shuler. “Clearly, David Altshuler is a a
Sleader in the field of genetic map-
ping, and the HapMap is a big, am- a
tbitious project that will be useful forapping genetic diseases, and that
ap will be very useful to many,
any geneticists,” says Snyder.
Similarly, Stuart Schreiber is a
orld leader in chemical biology
enomics,” says Snyder. “A lot of
eople collaborate with his group
or screening, and I don’t expect
hat to change even though many
niversities, including Yale, are set-
ing up their own chemical genom-
cs groups.”
On select projects, collaborations
lso include for-profit companies.
Companies may participate with
s in certain areas affecting global
ealth, like malaria and TB, where
hey can contribute to societal ben-
fit and can also enjoy the benefit
f the goodwill,” says Schreiber. “We
ope to be a receptor for forward-
hinking private sector companies
ike that.” Yet Schreiber acknowl-
dges that this type of research col-
aboration is the exception for a
ompany. Kleyn adds that collabo-
ations with for-profit companies
ould be considered only when
here would be no restrictions on
isseminating information into the
ublic domain. “The funder would
ain by overall acceleration of the
ield,” he says. In the public/private
NAi Consortium project, phar-
aceutical companies Bristol-Myers
quibb, Eli Lilly & Co., and Novartis
G and other academic centers are
upplying $18 million over three
ears to fund the production of
nhibitory RNAs. “The companies
enefit by working with the top re-
earchers in the field and accelerat-
ng their own pipelines,” Kleyn says,
and the institute benefits by get-
ing the reagents, tools, the tech-
ologies out there into the public
omain to advance medicine.”
“The relationships we focus on
ith for-profit companies are those
here the companies are comfort-
ble with the idea that the project
ill be a public domain project,”
ays Kleyn. The Broad Institute’s
ollaboration with Novartis on the
enetics of type 2 diabetes is an ex-
mple. “There is an understanding
hat deciphering the genetics of
omplex disease is a fundamental,
arly-stage research program and
nlikely to immediately deliver ther-
peutic benefit,” says Kleyn. Adds
nyder, “The Broad already gener-
tes sequences they are putting out
o the whole scientific community,and lots of people use them. The in-
formation they generate will defi-
nitely be used very extensively. I
would expect lots of collaborations
between the Broad and others in
the field, particularly as we learn
more about them.”
Multiple Funding Sources
Only about 10% of the Institute’s
funding derives from the original
Broad gift. “That 10% is intentionally
used to fund otherwise hard-to-fund
research, the truest earliest research
with no preliminary results based on
good ideas,” says Schreiber. “We en-
courage the growth of the Broad by
asking for proposals for science that
is very high risk but, if successful,
would transform science and soci-
ety.” These projects are funded ini-
tially only for 12 months. The initial
data produced are expected to en-
able the projects to generate their
own sustaining funding. Ninety per-
cent of the institute’s funding comes
from the government, philanthropic
sources, and nonprofit institutions,
and this funding supports more ad-
vanced science through the peer-
review process. The bulk of that
90% also supports the scientific
platforms.
“It is a fantastic time to do impor-
tant work in medical illness with a
genetic basis,” says Scolnick. “I
sensed that from the outside, but I
now am really impressed that we
are in a unique time to be able to
apply modern human genetics to
medical disease. Eric Lander wants
the Broad to make seminal discov-
eries about currently very poorly
understood diseases. He has a vi-
sion of what can be done to under-
stand really difficult medical dis-
eases with a genetic basis that is
inspiring.”
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